← Back to Search

Behavioural Intervention

Head Mounted Eye Tracking Device for Age-Related Macular Degeneration (HETALCEV Trial)

N/A
Waitlist Available
Led By Erik van Kuijk, MD, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Central vision loss from bilateral central scotomas
18 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

HETALCEV Trial Summary

This trial assesses a device that uses eye trackers and real-time image processing to help people with central vision loss.

Who is the study for?
This trial is for adults over 18 with central vision loss due to bilateral central scotomas, who can pass a basic mental status exam. It's not suitable for those who show cognitive impairment on the Mini-Mental State Examination.Check my eligibility
What is being tested?
The study tests a Head Mounted Display (HMD) device that tracks eye movement and remaps text/images around blind spots in real-time. Participants will try the HMD with and without this remapping feature to see how it affects their visual performance.See study design
What are the potential side effects?
Potential side effects are not detailed but may include discomfort from wearing the HMD, eye strain, or headaches due to prolonged use of the device or from image processing like contrast enhancement.

HETALCEV Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have lost central vision in both eyes.
Select...
I am 18 years old or older.

HETALCEV Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reading speed

HETALCEV Trial Design

2Treatment groups
Active Control
Group I: small scotoma using Head Mounted Display No re-mappingActive Control2 Interventions
patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
Group II: Large scotoma using Head Mounted Display PLUS re-mappingActive Control2 Interventions
patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,367 Previous Clinical Trials
1,587,501 Total Patients Enrolled
Erik van Kuijk, MD, PhDPrincipal InvestigatorUniversity of Minnesota

Media Library

Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV) (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT02829606 — N/A
Age-Related Macular Degeneration Research Study Groups: small scotoma using Head Mounted Display No re-mapping, Large scotoma using Head Mounted Display PLUS re-mapping
Age-Related Macular Degeneration Clinical Trial 2023: Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV) Highlights & Side Effects. Trial Name: NCT02829606 — N/A
Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV) (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02829606 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the magnitude of involvement in this trial?

"Indeed, the information on clinicaltrials.gov confirms that this medical experiment is actively enrolling people. The initiative was initially posted in April 2016 and recently updated in March 2022 with a call for 70 participants from one centre."

Answered by AI

Are there any current opportunities for participants to join this scientific experiment?

"According to the latest updates on clinicaltrials.gov, this study is still seeking volunteers. This particular medical trial was first posted on April 1st 2016 and has recently been edited as of March 25th 2022."

Answered by AI
~1 spots leftby Mar 2025